Article

Addressing Exclusivity Issues During the COVID-19 Pandemic and Beyond

2021-08-05

Abstract excerpt

Almost every aspect of the COVID-19 response, from vaccines, diagnostics, and therapeutics to medical equipment, tracking systems, software, and other innovations, are or will become subject to some form of exclusive rights. Many of these involve intellectual property rights (IPRs). By offering innovators the exclusive right to exploit their innovations while recouping the costs of research, development, and other...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 69b8d412-3522-5aa4-a9b3-c2a4049bb384
DOI: 10.2139/ssrn.3889894

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Addressing Exclusivity Issues During the COVID-19 Pandemic and BeyondDOI 10.2139/ssrn.3889894Read

The Intellectual Property of COVID-19Semantic proximity Read

Beyond Traditional IP: Addressing Regulatory BarriersSemantic proximity Read

Recalibrating Patent Protection for COVID-19 Vaccines: A Path to Affordable Access and Equitable DistributionSemantic proximity Read

Compelling Trade Secret TransfersSemantic proximity Read

COVID-19 Trade Secrets and Information Access: An OverviewSemantic proximity Read

The Role of Intellectual Property Rights on Access to Medicines in the WHO African Region: 25 Years After the TRIPS AgreementSemantic proximity Read

Prepared Oral Statement of Professors David S. Levine and Joshua D. Sarnoff in ITC Investigation 332-996, on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and Trips Agreement FlexibilitiesSemantic proximity Read

§ 1498: A Guide to Government Patent Use, a Path to Licensing and Distributing Generic DrugsSemantic proximity Read

Constitutional Challenges to the OSHA Covid-19 Vaccination MandateSemantic proximity Read

Innovation Institutions and COVID-19, Part IISemantic proximity Read

Global Patterns in Access and Benefit-Sharing: A Comprehensive Review of National PoliciesSemantic proximity Read

Ethical and human subject burdens of trials conducted to evaluate biosimilarsSemantic proximity Read